Leukemia Therapy Shows Potent Activity Against Rare Ovarian Cancer, Study Finds

Leukemia Therapy Shows Potent Activity Against Rare Ovarian Cancer, Study Finds
Ponatinib, an approved leukemia therapy sold under the brand name Iclusig, may be effective against tumors in a rare and aggressive form of ovarian cancer, research suggests. Led by researchers at the Translational Genomics Research Institute (TGen), the study, “Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition,” was published in the journal Clinical Cancer Research. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and highly malignant ovarian cancer that has been diagnosed in women from 14 months to 47 years of age. The most effective treatment is surgery followed by high doses of chemotherapy, radiation, and stem cell replacement, but the treatment is very toxic and response rates are low. "Current treatment for this devastating cancer has such poor response rates and extreme toxicity that we must find better therapeutics," Jeffrey Trent, PhD, TGen's president and research director and senior author of the study, said in a
Subscribe or to access all post and page content.